{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:25:49Z","timestamp":1794435949465,"version":"4.9.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019691","name":"Faculty of Medicine and Dentistry, University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011775","name":"BC Children's Hospital Foundation","doi-asserted-by":"publisher","award":["18\\u201313"],"award-info":[{"award-number":["18\\u201313"]}],"id":[{"id":"10.13039\/100011775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000033","name":"Institute of Musculoskeletal Health and Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008630","name":"Children's Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["183719"],"award-info":[{"award-number":["183719"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013117","name":"International Fibrodysplasia Ossificans Progressiva Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012280","name":"Rare Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014407","name":"Ministry of Advanced Education, Government of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102937","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:04:19Z","timestamp":1776384259000},"page":"102937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-base 2\u2032OMe-modified LNA and MOE gapmers selectively silence ACVR1R206H in fibrodysplasia ossificans progressiva"],"prefix":"10.1016","volume":"37","author":[{"given":"Saeed","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farin","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-3546","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102937_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1385\/BMM:3:3-4:183","article-title":"The phenotype of fibrodysplasia ossificans progressiva","volume":"3","author":"Kaplan","year":"2005","journal-title":"Clin. Rev. Bone Miner. Metab."},{"key":"10.1016\/j.omtn.2026.102937_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1242\/dmm.010280","article-title":"Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis","volume":"5","author":"Kaplan","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtn.2026.102937_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00774-008-0879-8","article-title":"Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP)","volume":"26","author":"Kaplan","year":"2008","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.omtn.2026.102937_bib4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/genes14122162","article-title":"Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers","volume":"14","author":"Anwar","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.omtn.2026.102937_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","article-title":"Fibrodysplasia ossificans progressiva","volume":"22","author":"Kaplan","year":"2008","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.omtn.2026.102937_bib6","article-title":"The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited","volume":"2012","author":"Verma","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.omtn.2026.102937_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2026.102937_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000365770","article-title":"Fibrodysplasia ossificans progressiva: Clinical course, genetic mutations and genotype-phenotype correlation","volume":"5","author":"H\u00fcning","year":"2014","journal-title":"Mol. Syndromol"},{"key":"10.1016\/j.omtn.2026.102937_bib10","doi-asserted-by":"crossref","first-page":"366ra163","DOI":"10.1126\/scitranslmed.aaf1090","article-title":"Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification","volume":"8","author":"Dey","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102937_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-02872-2","article-title":"Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva","volume":"9","author":"Lees-Shepard","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102937_bib12","first-page":"1","article-title":"the Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations (Update: July 2024)","author":"Kaplan","year":"2024","journal-title":"Proc Intl Clin Council FOP"},{"key":"10.1016\/j.omtn.2026.102937_bib13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/bja\/64.2.246","article-title":"Fibrodysplasia ossificans progressiva","volume":"64","author":"Newton","year":"1990","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.omtn.2026.102937_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153792","article-title":"Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1","volume":"132","author":"Aykul","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.omtn.2026.102937_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95042","article-title":"Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva","volume":"6","author":"Williams","year":"2021","journal-title":"JCI insight"},{"key":"10.1016\/j.omtn.2026.102937_bib16","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1038\/s41467-022-33956-9","article-title":"Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102937_bib17","article-title":"Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions","volume":"15","author":"Shaikh","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.omtn.2026.102937_bib18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bcp.13823","article-title":"Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"85","author":"Wentworth","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102937_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/gt.2011.193","article-title":"Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva","volume":"19","author":"Takahashi","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/gt.2011.152","article-title":"Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting","volume":"19","author":"Kaplan","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib22","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1242\/dev.126.11.2551","article-title":"The type I serine\/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo","volume":"126","author":"Gu","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.omtn.2026.102937_bib23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/dbio.1999.9378","article-title":"Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis","volume":"213","author":"Mishina","year":"1999","journal-title":"Dev. Biol."},{"key":"10.1016\/j.omtn.2026.102937_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mod.2003.12.003","article-title":"Craniofacial defects in mice lacking BMP type I receptor Alk2 in neural crest cells","volume":"121","author":"Dudas","year":"2004","journal-title":"Mech. Dev."},{"key":"10.1016\/j.omtn.2026.102937_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/nat.2021.0009","article-title":"Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1R206H Transcript and Inhibit Osteogenic Differentiation","volume":"32","author":"Maruyama","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-4781(99)00148-7","article-title":"Molecular mechanisms of action of antisense drugs","volume":"1489","author":"Crooke","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2026.102937_bib27","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/pharmaceutics15041130","article-title":"Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies","volume":"15","author":"Anwar","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2026.102937_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102937_bib29","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"143","article-title":"The medicinal chemistry of oligonucleotides","author":"Swayze","year":"2007"},{"key":"10.1016\/j.omtn.2026.102937_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense Oligonucleotide Therapies:The Promise and the Challenges from a Toxicologic Pathologist\u2019s Perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2026.102937_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib32","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1093\/nar\/gku142","article-title":"Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides","volume":"42","author":"Burdick","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kft278","article-title":"Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: Evidence of distinct pathways contributing to non-target mediated toxicity in mice","volume":"138","author":"Kakiuchi-Kiyota","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtn.2026.102937_bib34","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.1093\/nar\/gkv857","article-title":"In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization","volume":"43","author":"Kamola","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102937_bib36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/nat.2015.0576","article-title":"Development of a method for profiling protein interactions with LNA-modified antisense oligonucleotides using protein microarrays","volume":"26","author":"Kakiuchi-Kiyota","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.omtn.2017.07.003","article-title":"Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs","volume":"8","author":"Kamola","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102937_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","article-title":"A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides","volume":"10","author":"Dieckmann","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102937_bib40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.omtn.2017.05.011","article-title":"Electronic Structures of LNA Phosphorothioate Oligonucleotides","volume":"8","author":"Bohr","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102937_bib41","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/nar\/gky060","article-title":"Acute hepatotoxicity of 2 fluoro-modified 5\u201310\u20135 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib42","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/nat.2012.0366","article-title":"Chemical modification study of antisense gapmers","volume":"22","author":"Stanton","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1089\/nat.2013.0436","article-title":"Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern","volume":"23","author":"Hagedorn","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib44","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1093\/nar\/gkv298","article-title":"2\u2032-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF","volume":"43","author":"Shen","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib45","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102937_bib46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102937_bib47","doi-asserted-by":"crossref","first-page":"15438","DOI":"10.1073\/pnas.1510540112","article-title":"Neofunction of ACVR1 in fibrodysplasia ossificans progressiva","volume":"112","author":"Hino","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102937_bib48","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1074\/jbc.M801681200","article-title":"Constitutively activated ALK2 and increased SMAD1\/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva","volume":"284","author":"Fukuda","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102937_bib49","doi-asserted-by":"crossref","first-page":"22542","DOI":"10.1074\/jbc.M109.094557","article-title":"Molecular consequences of the ACVR1R206H mutation of fibrodysplasia ossificans progressiva","volume":"285","author":"Song","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102937_bib50","doi-asserted-by":"crossref","first-page":"10649","DOI":"10.1093\/nar\/gkx709","article-title":"Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides","volume":"45","author":"Bailey","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib51","doi-asserted-by":"crossref","first-page":"10865","DOI":"10.1093\/nar\/gkz771","article-title":"Kinetic and subcellular analysis of PS-ASO\/protein interactions with P54nrb and RNase H1","volume":"47","author":"Vickers","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib52","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/hum.2022.023","article-title":"Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles","volume":"33","author":"Eekhoff","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib53","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.omtn.2022.05.024","article-title":"RNA modifications can affect RNase H1-mediated PS-ASO activity","volume":"28","author":"Doxtader Lacy","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102937_bib54","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/nar\/gkx056","article-title":"Managing the sequence-specificity of antisense oligonucleotides in drug discovery","volume":"45","author":"Hagedorn","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102937_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-022-01709-z","article-title":"Palovarotene: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102937_bib56","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/ajhp\/zxad229","volume":"80","year":"2023","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.omtn.2026.102937_bib57","series-title":"Statement Regarding Palovarotene from the International Clinical Council (ICC) on FOP","year":"2013"},{"key":"10.1016\/j.omtn.2026.102937_bib58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44162-024-00032-3","article-title":"Palovarotene approved as first treatment for fibrodysplasia ossificans progressiva (FOP)","volume":"3","author":"Talha","year":"2024","journal-title":"J. Rare Dis."},{"key":"10.1016\/j.omtn.2026.102937_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11825-019-00279-y","article-title":"Genetics and future therapy prospects of fibrodysplasia ossificans progressiva","volume":"31","author":"Rauner","year":"2020","journal-title":"Medizinische Genet."},{"key":"10.1016\/j.omtn.2026.102937_bib60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13318-024-00926-z","article-title":"Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults","volume":"50","author":"Yang","year":"2025","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.omtn.2026.102937_bib61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.102937_bib62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14740338.2024.2447072","article-title":"Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?","volume":"24","author":"Tang","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.omtn.2026.102937_bib63","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.ymthe.2025.08.029","article-title":"The future of gene therapy: Safer vectors, sharper focus","volume":"33","author":"Chamberlain","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib64","doi-asserted-by":"crossref","first-page":"8282","DOI":"10.3390\/ijms26178282","article-title":"AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies","volume":"26","author":"Moldavskii","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.102937_bib65","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/med.22036","article-title":"The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution","volume":"44","author":"Kachanov","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.omtn.2026.102937_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102937_bib67","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","article-title":"Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"29","author":"Di Rocco","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102937_bib68","series-title":"ASBMR Annual Meeting","article-title":"LB 596 - Inhibition of MMP9 as a novel treatment strategy for Fibrodysplasia Ossificans Progressiva (FOP): Safety analysis of the anti-MMP9 antibody Andecaliximab in development for FOP","author":"Wenkert","year":"2024"},{"key":"10.1016\/j.omtn.2026.102937_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp8334","article-title":"An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva","volume":"16","author":"Davis","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102937_bib70","article-title":"Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.102937_bib71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s44337-026-00561-4","article-title":"Advances in genetic and pharmacological therapeutic strategies for fibrodysplasia ossificans progressiva","volume":"3","author":"Maurya","year":"2026","journal-title":"Discov. Med."},{"key":"10.1016\/j.omtn.2026.102937_bib72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtn.2026.102937_bib73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.omtn.2020.01.036","article-title":"Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats","volume":"20","author":"Di Martino","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102937_bib74","series-title":"Antisense Drug Technol. Princ. Strateg","first-page":"183","article-title":"Basic principles of the pharmacokinetics of antisense oligonucleotide drugs","author":"Levin","year":"2007"},{"key":"10.1016\/j.omtn.2026.102937_bib75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.omtn.2026.102937_bib76","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/nat.2019.0805","article-title":"The Pharmacokinetics of 2\u2019-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy","volume":"29","author":"Bosgra","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102937_bib77","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/08958378.2014.907587","article-title":"Local and systemic tolerability of a 2\u2032O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-\u03b1 delivery by inhalation in mouse and monkey","volume":"26","author":"Fey","year":"2014","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.omtn.2026.102937_bib78","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.omtn.2026.102937_bib79","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.3390\/molecules26175420","article-title":"Chemistry of Peptide-Oligonucleotide Conjugates: A Review","volume":"26","author":"Klabenkova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2026.102937_bib80","series-title":"Muscular Dystrophy Association (MDA) Clinical & Scientific Conference","article-title":"The FORCETM Platform Achieves Robust and Durable DUX4 Suppression and Improves Muscle Function in a Facioscapulohumeral Muscular Dystrophy Mouse Model","author":"Desjardins","year":"2025"},{"key":"10.1016\/j.omtn.2026.102937_bib81","series-title":"2024 FSHD Society International Research Congress","article-title":"Interim Results from FORTITUDETM, a Randomized Phase 1\/2 Trial Evaluating AOC 1020 in Adults with FSHD","author":"Statland","year":"2024"},{"key":"10.1016\/j.omtn.2026.102937_bib82","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160516","article-title":"DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration","volume":"8","author":"Aslesh","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.102937_bib83","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102937_bib84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10974-024-09688-2","article-title":"Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy","volume":"46","author":"Chwalenia","year":"2025","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.omtn.2026.102937_bib85","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/gtc.12587","article-title":"Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences","volume":"23","author":"Yoshida","year":"2018","journal-title":"Genes Cells"},{"key":"10.1016\/j.omtn.2026.102937_bib86","first-page":"183","article-title":"Morpholino-Mediated Exons 28\u201329 Skipping of Dysferlin and Characterization of Multiexon-skipped Dysferlin using RT-PCR, Immunoblotting, and Membrane Wounding Assay","volume":"2587","author":"Anwar","year":"2023"},{"key":"10.1016\/j.omtn.2026.102937_bib87","series-title":"Muscular Dystrophy Therapeutics: Methods and Protocols","first-page":"45","article-title":"Rapid Freezing of Skeletal and Cardiac Muscles Using Isopentane Cooled with Liquid Nitrogen and Tragacanth Gum for Histological, Genetic, and Protein Expression Studies","author":"Anwar","year":"2023"},{"key":"10.1016\/j.omtn.2026.102937_bib88","doi-asserted-by":"crossref","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an Ultrasensitive Noncompetitive Hybridization-Ligation Enzyme-Linked Immunosorbent Assay for the Determination of Phosphorothioate Oligodeoxynucleotide in Plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Anal. Biochem."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:36:45Z","timestamp":1794433005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126001083"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102937","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-base 2\u2032OMe-modified LNA and MOE gapmers selectively silence ACVR1R206H in fibrodysplasia ossificans progressiva","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102937"}}